Gardasil Clears Safety Review: No Link To VTE, Mini-Sentinel Study Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Study finds no increased risk of venous thromboembolism in more than 650,000 females vaccinated with the HPV vaccine; no labeling changes requested by FDA.
You may also be interested in...
Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge
Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.